The potential of proton beam radiation for palliation and reirradiation

被引:8
作者
Björk-Eriksson, T [1 ]
Ask, A
Glimelius, B
机构
[1] Sahlgrenska Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden
[2] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden
[3] Univ Uppsala Hosp, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden
[4] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden
关键词
D O I
10.1080/02841860500355967
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A group of Swedish oncologists and hospital physicists have estimated the number of patients in Sweden suitable for proton beam therapy. The estimations have been based on current statistics of tumour incidence, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours and normal tissues. If an estimated 1% of the palliative treatments can be administered by protons with substantial benefits to the patient, almost 100 patients per year in Sweden would be eligible. It is further estimated that around 150 patients per year in need of reirradiation would benefit from radiation with protons compared to photons.
引用
收藏
页码:918 / 920
页数:3
相关论文
共 15 条
[1]   Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor [J].
Chang, J ;
Clark, GM ;
Allred, DC ;
Mohsin, S ;
Chamness, G ;
Elledge, RM .
CANCER, 2003, 97 (03) :545-553
[2]   SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS [J].
CLARK, GM ;
SLEDGE, GW ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :55-61
[3]   IDENTIFICATION OF AN OPTIMAL SUBGROUP FOR TREATMENT EVALUATION OF PATIENTS WITH BRAIN METASTASES USING RTOG STUDY-7916 [J].
DIENERWEST, M ;
DOBBINS, TW ;
PHILLIPS, TL ;
NELSON, DF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (03) :669-673
[4]   Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning [J].
Glass, TR ;
Tangen, CM ;
Crawford, ED ;
Thompson, I .
JOURNAL OF UROLOGY, 2003, 169 (01) :164-169
[5]   Intensity-modulated radiotherapy for lymphoma involving the mediastinum [J].
Goodman, KA ;
Toner, S ;
Hunt, M ;
Wu, EJ ;
Yahalom, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (01) :198-206
[6]   Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients [J].
Insa, A ;
Lluch, A ;
Prosper, F ;
Marugan, I ;
Martinez-Agullo, A ;
Garcia-Conde, J .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 56 (01) :67-78
[7]  
Jenis LG, 1999, CLIN ORTHOP RELAT R, P89
[8]   Application of biological effective dose (BED) to estimate the duration of symptomatic relief and repopulation dose equivalent in palliative radiotherapy and chemotherapy [J].
Jones, B ;
Cominos, M ;
Dale, RG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (03) :736-742
[9]  
KAWANAMI S, 1996, JPN J LUNG CANC, V36, P77
[10]  
KNOTTCRAIG CJ, 1993, J THORAC CARDIOV SUR, V105, P394